Skip to main content
Premium Trial:

Request an Annual Quote

Ah, the Promise

GlaxoSmithKline's CEO Andrew Witty says that overhauling the company's drug discovery operation was a "major upheaval" but is now showing results. According to Reuters, Witty also says that in the last 15 years, the drug industry floundered by basing the discovery process on combinatorial chemistry, genomics, and proteomics. "These were all supposed to transform productivity yet none of them did. It turns out, in my view, that research is much more of an art than a science," Witty says.